Curebase Chooses Amendola Communications for Strategic Public Relations and Social Media Services

Curebase is developing a new approach to the entire clinical trial process with a distinct DCT model that revolves around the patient's lifestyle, allowing for diverse studies with larger patient populations.

Fremont, CA: Amendola Communications, a nationally recognized, award-winning healthcare and technology public relations and marketing firm, has declared that Curebase, a company committed to democratizing access to clinical studies, has chosen the agency to launch a comprehensive media and communications program highlighting its innovative Decentralized Clinical Trial (DCT) software platform and work to make clinical trials not only more patient-centric but also faster and more cost-efficient. The decision was taken after an extensive review of other national agencies.

Curebase is developing a new approach to the entire clinical trial process with a distinct DCT model that revolves around the patient's lifestyle, allowing for diverse studies with larger patient populations. The Curebase platform enables sponsors, CROs, and physicians to conduct first-of-its-kind study designs in which patients participate both at home and in real-world settings using best-in-class software.